Mudra Kapoor

Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

Gregory J. Dore, Brian Conway, Yan Luo et al. · Journal of Hepatology · 2015 · 68 citations · Full text

Stable Liposome in Cosmetic Platforms for Transdermal Folic acid delivery for fortification and treatment of micronutrient deficiencies

Mudra Kapoor, Anisha D’Souza, Noorjahan Aibani et al. · Scientific Reports · 2018 · 47 citations · Full text

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection

Eric Lawitz, G. W. Sullivan, M. Rodríguez‐Torres et al. · Journal of Infection · 2014 · 42 citations · Full text

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

Eric Lawitz, T. Marbury, Andrew Campbell et al. · Journal of Hepatology · 2012 · 24 citations

Antiviral Compound, Neurovirology, Immunology +10

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

Grace Sullivan, M. Rodriques-Torres, E. Läwitz et al. · Journal of Hepatology · 2012 · 23 citations

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +6